Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Rasmus Stilling Tougaard
  • Anders Jorsal
  • Lise Tarnow, North Zealand's University Hospital, Hillerød, Denmark.
  • ,
  • Nils Henrik Hansson, Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • ,
  • Caroline Kistorp, Department of Internal Medicine and Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • ,
  • Morten Schou, Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • ,
  • Roni Nielsen
  • ,
  • Allan Flyvbjerg, Steno Diabetes Center Copenhagen, The Capital Region of Denmark and University of Copenhagen, Gentofte, Denmark.
  • ,
  • Lars Videbaek, From the Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Odense, Denmark; Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • ,
  • Henning Mølgaard
  • Jens Cosedis Nielsen
  • Ida Gustafsson, Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
  • ,
  • Henrik Wiggers

Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.

Original languageEnglish
JournalScandinavian Cardiovascular Journal
Pages (from-to)1-6
Number of pages6
ISSN1401-7431
DOIs
Publication statusE-pub ahead of print - 15 Apr 2020

See relations at Aarhus University Citationformats

ID: 184617815